Ascendis Pharma A/S (ASND)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND). Investors who purchased Ascendis securities are encouraged to obtain additional information and assist the investigation.          

The investigation concerns whether Ascendis has violated federal securities laws.

On April 3, 2023, Ascendis issued a press release “announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments.  The deficiencies were not disclosed in the letter.”  On this news, Ascendis’s American depositary receipt (“ADR”) price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023.

If you are aware of any facts relating to this investigation or purchased Ascendis shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.